Melinta will beef up its antibiotics pipeline after a merger with troubled Cempra
Just weeks after Melinta Therapeutics completed an R&D odyssey with an FDA approval for the antibiotic delafloxacin (Baxdela), the biotech has struck a deal to merge troubled Cempra $CEMP into the company, taking over its antibiotics pipeline and one approved therapy.
Melinta investors — who come out of the deal with a public listing on Nasdaq — will wind up just barely on top, with 52% of the shares in the combined operation, which retains the Melinta name.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.